Skip Navigation

Division of AIDS (DAIDS)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Overview

The Division of Acquired Immune Deficiency Syndrome (DAIDS) was formed in 1986 to develop and implement the national research agenda to address the HIV/AIDS epidemic. Specifically, the mission of DAIDS is to help ensure an end to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV), supporting the development of therapies for HIV infection and its complications and co-infections, and supporting the development of vaccines and other prevention strategies. DAIDS accomplishes this through planning, implementing, managing, and evaluating programs through the following research programs and offices:

Click the text below to find or hide additional information.

Open All

Basic Sciences Program (BSP)

Basic science research efforts by NIAID-funded investigators have yielded important scientific contributions, including new targets for vaccines, drugs, and microbicides. The BSP, consisting of the Pathogenesis and Basic Research Branch, Targeted Interventions Branch and Epidemiology Branch, supports a major component of NIAID HIV/AIDS basic research efforts by carrying out the following activities:

  • Oversees grants and contracts that support basic and applied preclinical research
  • Encourages collaborative research with other scientific fields such as basic virology, immunology and pathobiology
  • Supports epidemiologic studies that help answer questions about HIV transmission and disease, including the Multicenter AIDS Cohort Study (MACS), Women's Interagency HIV Study (WIHS), and International Epidemiologic Databases to Evaluate AIDS (IeDEA)
  • Promotes research programs to discover novel therapeutic, vaccine, and microbicide strategies for the treatment and prevention of HIV
  • Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
  • Provides scientific guidance to grantees and contractors
  • Supports bioethics research on topics relevant to research on HIV/AIDS and its co-morbidities, including ethical issues in research on prevention, treatment and cure

For information on NIAID basic science research efforts, visit HIV Basic Science Research.

 

Therapeutics Research Program (TRP)

The evaluation of new drugs and therapeutic agents is a critical aspect of NIAID’s therapeutic research agenda. NIAID-sponsored therapeutics research has already had a dramatic impact on our understanding of the pathogenesis and clinical management of HIV infection over the last decade, and has helped define international guidelines for the treatment of primary HIV infection in adults and children and associated opportunistic infections and prophylactic regimens for these secondary infections, identify biological markers for predicting a drug's effectiveness and disease progression, and set the standard for use of antiretroviral drugs for preventing mother-to-infant transmission.

The TRP, which is divided into four branches: Drug Development and Clinical Sciences Branch, HIV Research Branch, Complications and Co-Infections Research Branch, and the Pediatric Medicine Branch, carries out the following therapeutic research activities:

  • Oversees grants, contracts, and cooperative agreements that support preclinical and clinical therapeutic research, and in particular, the Centers for AIDS Research (CFAR), AIDS Clinical Trials Group (ACTG), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
  • Develops the scientific agenda for clinical research of therapies to treat HIV and AIDS, related retroviruses, and HIV-related complications and coinfections
  • Promotes research programs to discover novel therapeutic strategies for the treatment of HIV
  • Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
  • Works with the pharmaceutical industry and the Food and Drug Administration to facilitate the evaluation and approval of new therapeutics
  • Provides scientific guidance to grantees and contractors

For more information on NIAID therapeutic research efforts, visit HIV/AIDS Therapeutics Research.

 

Vaccine Research Program (VRP)

The discovery and development of an HIV/AIDS vaccine for the prevention of HIV infection is one of the top priorities at NIAID. As such, the VRP, which is divided into the Preclinical Research and Development Branch and Vaccine Clinical Research Branch, supports basic, preclinical, and clinical research of candidate vaccines through the following activities:

  • Oversees grants, contracts, and cooperative agreements that support preclinical and clinical vaccine research, including the HIV Vaccine Trials Network (HVTN) and Center for HIV/AIDS Immunology (CHAVI)
  • Fosters evaluation of the safety and efficacy of vaccine candidates
  • Promotes research programs to discover novel vaccine strategies for the treatment of HIV
  • Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
  • Works with the pharmaceutical industry and the Food and Drug Administration to facilitate the evaluation and approval of new vaccines
  • Provides scientific guidance to grantees and contractors

For more information on NIAID HIV vaccine research efforts, visit HIV/AIDS Vaccine Research.

 

Prevention Sciences Program (PSP)

The development of new and more effective non-vaccine methods and strategies to prevent HIV infection is an important component of NIAID’s HIV research agenda. DAIDS supports research on biomedical and behavioral prevention approaches through the Prevention Sciences Program (PSP), which includes the Microbicide Research Branch and the Prevention Research Branch, that carries out the following activities:

  • Oversees grants, contracts, and cooperative agreements that support preclinical and clinical prevention research, including the HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN)
  • Promotes research programs to discover non-vaccine prevention strategies
  • Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
  • Works with the pharmaceutical industry and the Food and Drug Administration to facilitate the evaluation and approval of new prevention strategies
  • Provides scientific guidance to grantees and contractors

For more information about NIAID HIV prevention research efforts, visit HIV/AIDS Prevention Science Research.

 

Office for Policy in Clinical Research Operations (OPCRO)

The OPCRO manages and supports DAIDS clinical research and helps ensure compliance with applicable regulations, standards, and good clinical practice guidelines; study participant safety and welfare; and study quality and integrity. OPCRO, which includes the Clinical Research Resources Branch, Human Subjects Protection Branch, Policy, Training, and Quality Assurance Branch, Regulatory Affairs Branch, Pharmaceutical Affairs Branch, Clinical Trials Agreements Team, and Safety and Pharmacovigilance Team, carries out the following key functions:

  • Develops and maintains division-wide clinical research polices and standard procedures and coordinates related training and quality assurance activities
  • Manages a portfolio of DAIDS contracts for independent site monitoring
  • Implements the DAIDS safety monitoring and reporting, related safety standards, and pharmacovigilance capacity
  • Manages Investigational New Drug Applications
  • Provides pharmaceutical expertise
  • Develops Clinical Trial Agreements
  • Protects the rights and well-being of clinical research subjects
 

Scientific Communications and Information Branch (SCIB)

The SCIB oversees the communications, reporting, and other operations for DAIDS by performing the following key functions:

  • Communicates with the biomedical community, Congress, other specialized groups, and to the general public
  • Coordinates DAIDS activities with other NIAID and NIH Offices and Institutes
  • Manages DAIDS advisory committees
  • Coordinates Freedom of Information Act (FOIA) requests
 

Scientific Planning and Operations Branch (SPOB)

The SPOB oversees the long and short term planning, budget, and scientific and administrative activities for DAIDS by performing the following key functions:

  • Coordinates annual scientific and budget planning, and allocates and monitors resources
  • Provides administrative support and guidance for grants and contracts
  • Coordinates the development of new funding opportunities
  • Assesses research programs, DAIDS operations or other activities
 

Office of Clinical Site Oversight (OCSO)

The OCSO facilitates the clinical research of the DAIDS scientific programs by overseeing clinical sites associated with the NIAID-sponsored HIV/AIDS clinical trials networks. As such, they perform the following key functions:

  • Oversees grants of network clinical trials units (CTU) and clinical research sites (CRS) that participate in the HIV/AIDS clinical trials networks
  • Establishes new clinical sites around the world
  • Evaluates and monitors the administration, finances, and performance of existing clinical sites
  • Works with other government agencies, other Institutes at the National Institutes of Health, and the HIV/AIDS clinical trial networks
  • Verifies that optimal safeguards are employed for participant safety and that high quality research practices are utilized
  • Oversees the DAIDS clinical research standards, policies and procedures that are used by clinical sites
  • Monitors clinical site progress of enrolling of underserved populations and ensuring community representation
  • Organizes and/or participates in program and regional meetings as necessary

Last Updated March 17, 2014